SNO 2021: The ID01 Inhibitor Indoximod Has Demonstrated Safety and Trended Toward Efficacy in HGG
The investigational drug was given in combination with temozolomide, bevacizumab, and SRS.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.